Hims & Hers Health, Inc. HIMS
16.02 USD -1.03 (-6.04%)
Regular-session close
15.93 -0.09 -0.59%
After hours · Nov 19, 7:59 PM ET
15.98 Day range 17.28
13.74 52-week range 40.99
- YTD
- -50.66%
- 1 year
- -55.29%
Benzinga news
benzinga.com Hims & Hers Under Fire: Five More States Join Federal Crackdown Over Alleged Privacy Violations The FTC and seven states expanded their lawsuit against Hims & Hers over deceptive recurring subscriptions and sensitive health data leaks.
benzinga.com Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board Hims & Hers Health Inc. (NYSE: HIMS) had a busy week that included Q3 earnings miss, a board appointment and analyst price target changes.benzinga.com Five States Join FTC Lawsuit Alleging Hims and Hers Engaged in Deceptive and Unlawful Privacy Practices https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices
benzinga.com Jefferies Maintains Hold on Hims & Hers Health, Lowers Price Target to $24 Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and lowers the price target from $31 to $24.
benzinga.com Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity Hims & Hers stock dropped after a Q3 loss and guidance cut, but Needham reaffirmed its Buy rating, seeing the post-earnings pullback as an entry point.benzinga.com Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $25 Morgan Stanley analyst Craig Hettenbach maintains Hims & Hers Health (NYSE:HIMS) with a Equal-Weight and lowers the price target from $28 to $25.
benzinga.com These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results Hims & Hers missed Q3 FY26 earnings and revenue estimates, cut guidance, and shares fell 13%; analysts revised price targets.benzinga.com Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27 Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.
benzinga.com Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? Hims & Hers Health Inc. (NYSE: HIMS) shares are trading lower Tuesday after the company reported worse-than-expected Q3 results late Monday.benzinga.com Needham Maintains Buy on Hims & Hers Health, Lowers Price Target to $32 Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $42 to $32.
benzinga.com Hims & Hers Health Q3 2026 Earnings Call Transcript Hims & Hers Health (NYSE:HIMS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Hims & Hers Stock Slips Further as Q3 Print Disappoints Here's a detailed look inside the Q3 earnings report from Hims & Hers Health.benzinga.com Hims & Hers Health Q3 EPS $(0.14) Misses $0.08 Estimate, Sales $890.373M Miss $892.888M Estimate Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.08 by 275 percent. This is a 255.56 percent decrease over earnings of…
benzinga.com Hims & Hers Health Narrows FY2026 Sales Guidance from $3.100B-$3.300B to $3.130B-$3.150B vs $3.209B Est Hims & Hers Health (NYSE:HIMS) narrows FY2026 sales outlook from $3.100 billion-$3.300 billion to $3.130 billion-$3.150 billion vs $3.209 billion estimate.
benzinga.com Hims & Hers Health Sees Q4 Sales $875.000M-$895.000M vs $953.446M Est Hims & Hers Health (NYSE:HIMS) sees Q4 sales of $875.000 million-$895.000 million vs $953.446 million analyst estimate.
benzinga.com Hims & Hers Stock Plunges Before Earnings: What to Watch Hims & Hers Health shares are plummeting Monday ahead of its Q3 earnings report, which is scheduled for release after the market close.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Hims & Hers Short Interest Climbs to 23% Ahead of Earnings: Can the Stock Break Out? Hims & Hers Health stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about 65% to the current $26.
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.benzinga.com Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit Hims & Hers seeks dismissal of a consumer lawsuit, arguing upfront disclosures refute claims about user privacy, billing, and cancellations.
